139 related articles for article (PubMed ID: 36856881)
1. Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids.
Billups SJ; Thai VK; Denkins J; Dettman IC; Rothman MS
Arch Osteoporos; 2023 Mar; 18(1):38. PubMed ID: 36856881
[TBL] [Abstract][Full Text] [Related]
2. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
3. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.
Curtis JR; Westfall AO; Allison JJ; Becker A; Casebeer L; Freeman A; Spettell CM; Weissman NW; Wilke S; Saag KG
Arthritis Rheum; 2005 Aug; 52(8):2485-94. PubMed ID: 16052570
[TBL] [Abstract][Full Text] [Related]
6. Rates of osteoporosis screening and treatment following vertebral fracture.
Barton DW; Behrend CJ; Carmouche JJ
Spine J; 2019 Mar; 19(3):411-417. PubMed ID: 30142455
[TBL] [Abstract][Full Text] [Related]
7. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America.
Soybilgic A; Tesher M; Wagner-Weiner L; Onel KB
Pediatr Rheumatol Online J; 2014; 12():24. PubMed ID: 25053923
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
9. Clinical risk factor status in patients with vertebral fracture but normal bone mineral density.
Kadri A; Binkley N; Daffner SD; Anderson PA
Spine J; 2022 Oct; 22(10):1634-1641. PubMed ID: 35680015
[TBL] [Abstract][Full Text] [Related]
10. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting.
Yood RA; Harrold LR; Fish L; Cernieux J; Emani S; Conboy E; Gurwitz JH
Arch Intern Med; 2001 May; 161(10):1322-7. PubMed ID: 11371261
[TBL] [Abstract][Full Text] [Related]
11. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
12. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
Majumdar SR; Morin SN; Lix LM; Leslie WD
Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
[TBL] [Abstract][Full Text] [Related]
13. Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway.
Apalset EM; Lunde A; Hoff M; Ehrenstein V; Tell GS
Arch Osteoporos; 2020 Aug; 15(1):121. PubMed ID: 32757143
[TBL] [Abstract][Full Text] [Related]
14. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
15. Secondary prevention of minor trauma fractures: the effects of a tailored intervention-an observational study.
van der Vet PCR; Kusen JQ; Rohner-Spengler M; Link BC; Houwert RM; Babst R; Henzen C; Schmid L; Beeres FJP
Arch Osteoporos; 2019 Mar; 14(1):44. PubMed ID: 30923963
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU study.
Roux C; Cooper C; Díez-Pérez A; Martinez L; Ortolani S; Gitlin M; Möller G; Shepherd S; Freemantle N
Osteoporos Int; 2011 Apr; 22(4):1227-36. PubMed ID: 20628731
[TBL] [Abstract][Full Text] [Related]
17. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
[TBL] [Abstract][Full Text] [Related]
18. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan.
Chitre MM; Hayes W
J Manag Care Pharm; 2008 Apr; 14(3):281-90. PubMed ID: 18439050
[TBL] [Abstract][Full Text] [Related]
19. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
20. Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.
Massafra U; Migliaccio S; Bancheri C; Chiacchiararelli F; Fantini F; Leoni F; Martin LS; Migliore A; Muccifora B; Napolitano C; Pastore R; Ragno A; Ronzoni S; Rotondi M; Tibaldi M; Villa P; Vinicola V; D'Erasmo E; Falaschi P; Minisola G
J Endocrinol Invest; 2013 Feb; 36(2):92-6. PubMed ID: 22398397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
